Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

The Boston biotech, which has several drugs in clinical trials to treat cystic fibrosis, said Thursday night it raised $191 million by selling 10.6 million shares for $18 each. The company also ...

Feb 7 (Reuters) - AbbVie (ABBV.N), opens new tab said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by ...

Several disease-modifying therapies (DMTs) can help change the disease course of MS. People with MS can also take other medications for symptoms, complications, and relapses. Multiple sclerosis ...

AbbVie Inc. (NYSE:ABBV) showed positive top-line growth from its immunosuppressive drugs, Skyrizi and Rinvoq. Abbvie’s management continues to work through the loss of exclusivity from Humira ...

Mental Health Medications: How Do They Work? There are several types of drugs available to treat mental illnesses. Some of the most commonly used are antidepressants, anti-anxiety drugs ...